Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Citation:
Park, K., Bennouna, J., Boyer, M., Hida, T., Hirsh, V., Kato, T., Lu, S., Mok, T., Nakagawa, K., O'Byrne, K., Paz-Ares, L., Schuler, M., Sibilot, D.M., Tan, E.H., Tanaka, H.,Wu, Y.L., Yang, J.C.H., Zhang, L., Zhou, C., Morten, A., Tang, W., Yamamoto, N. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer, Lung Cancer, 2019, 132, 126-131Download Item:
Abstract:
Objectives: With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. In this retrospective analysis of EGFR mutation-positive (Del19/L858R) patients receiving first-line afatinib in LUX-Lung 3, 6, and 7, we assessed uptake of, and outcomes following, subsequent therapies including the third-generation EGFR TKI, osimertinib.
Methods: Post-progression therapy data were prospectively collected during follow-up. Molecular testing of tumours at progression/discontinuation of afatinib was not mandatory. Duration of subsequent therapies, and survival following osimertinib, were calculated with Kaplan–Meier estimates.
Results: Among 553 patients who discontinued first-line afatinib, second-, third- and fourth-line therapy was administered in 394 (71%), 265 (48%), and 156 (28%) patients. The most common post-progression therapy was platinum-based chemotherapy (46%). Thirty-seven patients received subsequent osimertinib, 10 as second-line treatment. Median progression-free survival on afatinib in these 37 patients was 21.9 months. Median duration of osimertinib therapy was 20.2 months; median overall survival was not reached after a median follow-up of 4.7 years.
Conclusions: Most patients treated with first-line afatinib received subsequent therapy. Although limited by sample size, enrichment, and a retrospective nature, data from patients who received sequential afatinib and osimertinib are encouraging, warranting further investigation.
URI:
https://www.sciencedirect.com/science/article/pii/S0169500219304015http://hdl.handle.net/2262/89372
Author's Homepage:
http://people.tcd.ie/obyrneke
Author: O'Byrne, Ken
Publisher:
ElsevierType of material:
Journal ArticleURI:
https://www.sciencedirect.com/science/article/pii/S0169500219304015http://hdl.handle.net/2262/89372
Collections
Series/Report no:
Lung Cancer;132;
Availability:
Full text availableKeywords:
Afatinib, Non-small cell lung cancer, OsimertinibDOI:
http://dx.doi.org/10.1016/j.lungcan.2019.04.014Metadata
Show full item recordLicences: